MIV-150 (PC-815) is primarily investigated for its potential in preventing sexually transmitted infections (STIs), particularly HIV. It is being studied as a key component in intravaginal rings and microbicidal gels, which aim to provide sustained protection against viral transmission. The compound works by inhibiting viral replication, making it a promising candidate for use in populations at high risk of HIV infection. Additionally, its application in combination with other antiretroviral agents is being explored to enhance efficacy and reduce the likelihood of drug resistance. Research is ongoing to evaluate its safety, effectiveness, and potential for long-term use in preventive healthcare strategies.